Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Primary thyroid B-cell lymphoma: molecular insights into its clonal evolution and relapse.
J Pathol
February 2025
Department of Pathology, University of Cambridge, Cambridge, UK.
Primary thyroid lymphomas comprise largely extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (EMZL) and diffuse large B-cell lymphoma (DLBCL), followed by follicular lymphoma (FL). They commonly develop from a background of Hashimoto's thyroiditis (HT), where dysregulated immune responses trigger autoreactive infiltrates and drive clonal B-cell evolution. To understand how these lymphomas and their relapse evolve, we investigated 10 cases by mutation profiling, including five with metachronous lymphomas [primary lymphoma (EMZL = 4, DLBCL = 1) with local relapse (EMZL = 3, DLBCL = 2)], one composite EMZL and Epstein-Barr virus (EBV)-positive DLBCL, and four lymphomas (EMZL = 3, FL = 1) with prior or subsequent biopsy showing HT.
View Article and Find Full Text PDFIdentifying Subsets of Cancer Patients with an Increased Risk of Developing Cutaneous Melanoma: A Surveillance, Epidemiology, and End Results-Based Analysis.
JID Innov
January 2025
Department of Dermatology & Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Cancer survivors have an increased risk of developing second primary malignancies. We aimed to identify whether certain cancers lead to an increased risk of developing melanoma among cancer survivors. We evaluated the risk of developing cutaneous melanoma after the 20 most common cancers in the United States through the Surveillance, Epidemiology, and End Results database.
View Article and Find Full Text PDFMeasuring healthy life expectancy and determinants of poor perceived health: A population-based study among a subset of rare and common cancer survivors.
Cancer Epidemiol
February 2025
Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Background: As the survival proportions for rare cancers are on average worse than for common cancers, assessing the expected remaining life years in good health becomes highly relevant. This study aimed to estimate the healthy life expectancy (HLE) of a subset of rare and common cancer survivors, and to assess the determinants of poor perceived health in rare cancer survivors.
Methods: To calculate HLE, survival data from the population-based Netherlands Cancer Registry of survivors of a rare cancer (i.
The Cancer Incidence Pattern in Isfahan Province: An Industrial Region in the Central Part of Iran.
J Cancer Epidemiol
November 2024
Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- The study analyzed age-standardized incidence rates (ASRs) of various cancers in Isfahan province, Iran, using data from a local cancer registry covering 2014 to 2018.
- The registry recorded 42,994 new cancer cases, with a majority being males, and showed strong quality indicators, such as a high microscopic verification rate.
- The most common cancers included prostate and bladder cancers in men, and breast cancer in women, with higher incidence rates for leukemia and non-Hodgkin lymphoma compared to national averages, indicating potential links to environmental factors in an industrial setting.
Primary Thyroid Lymphoma: A Rare Diagnosis Treated With Polatuzumab Vedotin.
J Investig Med High Impact Case Rep
November 2024
Department of Medicine, Kern Medical, Bakersfield, CA, USA.
Primary thyroid lymphoma is one of the rare and distinct type of extra nodal lymphomas originating within the thyroid gland. It accounts for less than 5% of all thyroid malignancies and 2% of extra nodal lymphomas. It predominantly affects older adults, with a higher incidence in women.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!